Eloralintide
Eloralintide is an investigational once-weekly amylin injection from Eli Lilly. Its phase 2 trial showed up to about 20% weight loss at 48 weeks, and phase 3 trials are under way. It is not approved.
Also searched as: LY3841136, eloralintide tirzepatide.
Educational information. This page does not give dosing instructions or tell you what to take. Ask a prescriber about your own care.
In plain English
Eloralintide (also LY3841136) is Eli Lilly's amylin drug. Amylin is a fullness hormone released with insulin. Unlike cagrilintide, which hits several related receptors, eloralintide was designed to target mainly one amylin receptor, called AMY1R.
In the phase 2 trial, 263 U.S. adults without diabetes lost between 9% and 20% of body weight over 48 weeks on the different weekly amounts, versus 0.4% on placebo. That uses the efficacy estimand, which counts people while they were taking the drug and generally shows larger numbers than analyses that include everyone who stopped.
Nausea and fatigue were the most common side effects. Lilly has started phase 3 trials and has registered another that combines eloralintide with tirzepatide. Eloralintide is not approved anywhere.
Brand names and products
A generic name identifies the drug itself. A brand name identifies one company's product. One drug can come in several products with different forms and approved uses, so the brand name often tells you more about what a prescription is for.
No brand name is recorded for this medicine because there is no approved product.
Approved and investigational. Every use of eloralintide is investigational. There is no approved product.
How it works
Eloralintide is a long-acting peptide that preferentially activates the amylin 1 receptor (AMY1R) over the closely related calcitonin and amylin 3 receptors, based on lab studies. In rats it reduced food intake and body weight mainly through loss of fat mass. The authors, who work for Lilly, suggest this selectivity may help with stomach and gut tolerability, but it has not been tested head-to-head against other amylin drugs.
Forms and approval status
| Form | How it is taken | U.S. status |
|---|---|---|
| Eloralintide injection (investigational) | Once weekly in trials. Available only inside clinical trials. | Not approved. Eli Lilly has started phase 3 trials: one in adults with obesity without type 2 diabetes (1,980 people), one in people whose weight has stayed high on a weekly incretin medicine (900 people), and one combining eloralintide with tirzepatide in type 2 diabetes that is not yet recruiting. |
What the trials found
These are group averages from published trials in adults without diabetes unless stated. See how to read trial numbers before comparing.
Eloralintide phase 2 (obesity)
Average change in body weight. Every bar uses one scale, 0 to 25 percent.
- People studied
- 263 adults in the U.S. with a BMI of 30 or more, or 27 or more plus a weight-related condition, without type 2 diabetes
- Length
- 48 weeks
- Compared with
- Placebo. Four fixed weekly amounts (1, 3, 6 and 9 mg) and two groups that raised the amount over time (6 to 9 mg and 3 to 9 mg)
- What was measured
- Average change in body weight at week 48
- Analysis approach
- Efficacy estimand: effects while people were taking the treatment as assigned. This usually shows larger weight loss than analyses that count everyone who stopped
- Other results
- The escalation groups lost about 20% (6 to 9 mg) and 16% (3 to 9 mg).
- Safety
- Nausea was the most common side effect: 11% (1 mg), 13% (3 mg), 64% (6 mg), 33% (9 mg), 54% (6 to 9 mg) and 25% (3 to 9 mg) vs 14% with placebo. Fatigue rose with the amount, from 0% at 1 mg to 43% at 9 mg, vs 12% with placebo.
- Limits
- Phase 2, so groups were small. Funded by the manufacturer. The headline figures use the efficacy estimand, so they likely overstate what people who stop early would see. The group was 78% women and 78% White. Nausea did not rise steadily with the amount, so the groups cannot be ranked by tolerability. Group averages do not predict one person's result.
Sources: Billings LK 2025
Safety
No FDA label exists for this medicine yet. The information below comes from published trial reports. The points below are a summary and may be incomplete.
Boxed warning and label notes
- Eloralintide injection (investigational): Not applicable. Not approved.
Warnings labels describe
- Not approved, so no official label exists. Safety information comes from trial reports.
- The phase 2 trial was small and short, so rare or long-term risks are unknown.
Most common in trials
- Nausea
- Fatigue
- Decreased appetite
- Headache
Less common but serious
- The phase 2 abstract does not list serious events. The phase 1 study reported one serious event, judged unrelated to eloralintide, and no deaths.
What is still unknown
- Phase 3 results. The main obesity trial has a registered primary completion date of March 2028.
- Whether the weight loss holds up when all people who stop early are counted. The phase 2 headline uses the efficacy estimand.
- The best amount and dose-increase schedule.
- How it compares with incretin drugs, and how much it adds on top of tirzepatide.
- Long-term safety, including fatigue, which rose with the amount.
Compiled from public information: FDA-approved labels, manufacturer websites, ClinicalTrials.gov and published journal articles. Sources are listed at the bottom of this page.
Sources
- Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial Billings LK, et al. Lancet. 2025;406(10520):2631-2643. PMID 41207310. Funding: Eli Lilly. Journal article
- Eloralintide phase 3 in adults with obesity or overweight, without type 2 diabetes (NCT07321886) ClinicalTrials.gov identifier NCT07321886. Sponsor: Eli Lilly and Company. Trial registry
- Eloralintide in adults with persistent obesity treated with a weekly incretin (NCT07392190) ClinicalTrials.gov identifier NCT07392190. Sponsor: Eli Lilly and Company. Trial registry
- ClinicalTrials.gov U.S. National Library of Medicine. Trial registry
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: from discovery to clinical proof of concept Briere DA, et al. Mol Metab. 2025;102:102271. PMID 41109426. Funding: Eli Lilly. Journal article
- Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: phase 1 proof of concept Bhattachar S, et al. Diabetes Obes Metab. 2026;28(4):2651-2660. PMID 41559929. Funding: Eli Lilly. Journal article